RELATE-2 v01
Research type
Research Study
Full title
RELATE-2: A real-world observational study assessing the feasibility, acceptability and perceived impacts of digital apps for use with patients receiving Olaparib & Trastuzumab Deruxtecan (T-DXd)
IRAS ID
331541
Contact name
Sophie McGrath
Contact email
Sponsor organisation
AstraZeneca UK Limited
Clinicaltrials.gov Identifier
Px-03101, Px Reference number
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Safe and effective use of medical therapies, trastuzumab deruxtecan or olaparib, for breast cancer patients requires patient education and careful treatment monitoring by patients and care teams. The OWise app is co-designed with patients and clinicians to educate and support patients. It allows them to monitor their symptoms and share their collected data to discuss any concerns or issues in clinic visits ensuring optimal medical care. OWise further aims to provide patients with the knowledge and tools to improve their self-care as well as confidence to enhance the patient-physician conversation improving overall care and treatment situation.
This study will assess how feasible it is to use the OWise app during routine breast cancer care, to what extent patients accept and use it and how its adoption appears to impact patients and their quality of care. Results of this study will help guide ongoing efforts to improve clinical care, education and digital health support for breast cancer patients in order to improve patient-important health and quality of life outcomes and efficient use of resources.
Using OWise patients will fill out a brief set of questions about their experience using the app at the start of the study and every 3 months for the study duration. Anonymised data about use of the app, use of medical therapies and health and care experiences will be used to improve understanding of opportunities to improve care. The outcomes of the study are aimed at better understanding the value of the app to improve patient experience and care as well as its optimal clinical use.
REC name
South Central - Oxford B Research Ethics Committee
REC reference
23/SC/0318
Date of REC Opinion
14 Sep 2023
REC opinion
Favourable Opinion